USPSTF Recommendation Statement on Screening for Prostate Cancer



Media advisory: To contact the U.S. Preventive Services Task Force, email the Media Coordinator at or call 202-572-2044. The full report is available on the For The Media website.

Want to embed a link to this report in your story? Link will be live at the embargo time

Translation available: A translation in simplified Chinese is available below.



Bottom Line: The U.S. Preventive Services Task Force (USPSTF) recommends that men 55 to 69 who are interested in screening talk to their doctors about potential benefits and harms of screening for prostate cancer before deciding whether to undergo periodic prostate-specific antigen (PSA)-based screening. The USPSTF recommends against PSA-based screening for men 70 and older.

Background: The USPSTF routinely makes recommendations about the effectiveness of preventive care services. This latest statement is an update of the 2012 recommendation. Prostate cancer is one of the most common types of cancer that affects men. Many men with prostate cancer never experience symptoms and, without screening, would never know they have the disease.

The USPSTF Concludes:

Related material

The following related elements from The JAMA Network are also available on the For The Media website:

— A summary video is available for download or to embed on your website. Download the video as a high-quality MP4 file by clicking on this link and then right-clicking and selecting “save video as.” In addition, you may copy and paste the html code below to embed the video on your website. The transcript is available here.

— A podcast interview with Alex H. Krist, M.D., M.P.H., a member of the USPSTF and co-author of the recommendation statement. The transcript is available here.

Screening for Prostate Cancer US Preventive Services Task Force Recommendation Statement

Prostate-Specific Antigen–Based Screening for Prostate Cancer – Evidence Report and Systematic Review for the US Preventive Services Task Force

JAMA Oncology editorial: Prostate Cancer Screening—A New Recommendation for Meaningful Physician-Patient Conversations

JAMA Surgery editorial: USPTF Prostate Cancer Screening Recommendations— A Step in the Right Direction

JAMA Internal Medicine editorial: Implications of the New USPSTF Prostate Cancer Screening Recommendation—Attaining Equipoise

 — JAMA editorial: Prostate-Specific Antigen (PSA) Screening for Prostate CancerRevisiting the Evidence

JAMA Patient Page: Screening for Prostate Cancer

For more details and to read the full report, please visit the For The Media website.


Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

Note: More information about the U.S. Preventive Services Task Force, its process, and its recommendations can be found on the newsroom page of its website.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email


Translation in Simplified Chinese


禁止提前报道指令解除时间:201858 星期二,美国东部时间上午11

媒体咨询:联系美国预防服务工作组 (U.S. Preventive Services Task Force),请发电子邮件到媒体协调员 或打电话(202-572-2044)联系。



 概要: 美国预防服务工作组(USPSTF)建议有兴趣筛查的55至69岁的男性在决定是否接受基于前列腺特异性抗原(PSA)的定期筛查之前,与其医生讨论筛查前列腺癌的潜在的益处和危害。 根据《美国医学会杂志》(JAMA)发表的一份报告,USPSTF建议不要对70岁及以上的男性进行基于PSA的筛查。

背景资料:USPSTF经常就各种预防保健服务的有效性提出建议。 这一最新声明是对2012年建议的更新。 前列腺癌是影响男性的最常见的癌症类型之一。 许多患有前列腺癌的男性从未出现过症状,如果没有筛查,可能永远也不会知道自己患有这种疾病。


对于55至69岁的男性,决定定期进行基于PSA的前列腺癌筛查应该是个人的决定,并且应该事先与临床医生讨论该筛查的潜在的益处和危害。 筛查可能会为减少某些男性患前列腺癌的机会提供一个不大的潜在好处。 然而,许多男性会经历该筛查的潜在危害,包括假阳性结果,其需要额外的测试和可能的前列腺活检; 过度诊断和过度治疗; 以及治疗并发症,如失禁和勃起功能障碍等。在确定该筛查是否适用于某个个体时,患者和临床医生应考虑其家族史,种族/民族,共存的疾病状况,病人对筛查的益处,危害以及治疗导致的结果的评价,以及其它健康需要等。临床医生不应该对没有筛查意愿的男性进行筛查(C建议)。USPSTF建议不要对70岁及以上的男性进行基于PSA的前列腺癌筛查 (D建议)。

欲了解更多详情并阅读完整的研究报告,请访问For The Media网站:


Video embed code: